View in EDS HTML Full Text PDF Full Text

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.

Saved in:
Bibliographic Details
Title: Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
Authors: Okada AA; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan. aokada@e23.jp., Takahashi K; Department of Ophthalmology, Kansai Medical University, Osaka, Japan., Ohji M; Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan., Moon SC; Department of Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany., Machewitz T; Department of Research and Development, Bayer AG, Berlin, Germany., Sasaki K; Department of Medical Affairs and Pharmacovigilance, Bayer Yakuhin Ltd., Osaka, Japan.
Corporate Authors: ALTAIR Study Investigators
Source: Advances in therapy [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2984-2998. Date of Electronic Publication: 2022 May 03.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35503499
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Okada+AA%22">Okada AA</searchLink>; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo, 181-8611, Japan. aokada@e23.jp.<br /><searchLink fieldCode="AU" term="%22Takahashi+K%22">Takahashi K</searchLink>; Department of Ophthalmology, Kansai Medical University, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Ohji+M%22">Ohji M</searchLink>; Department of Ophthalmology, Shiga University of Medical Science, Otsu, Shiga, Japan.<br /><searchLink fieldCode="AU" term="%22Moon+SC%22">Moon SC</searchLink>; Department of Medical Affairs and Pharmacovigilance, Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Machewitz+T%22">Machewitz T</searchLink>; Department of Research and Development, Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Sasaki+K%22">Sasaki K</searchLink>; Department of Medical Affairs and Pharmacovigilance, Bayer Yakuhin Ltd., Osaka, Japan.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ALTAIR+Study+Investigators%22">ALTAIR Study Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228611864%22">Advances in therapy</searchLink> [Adv Ther] 2022 Jun; Vol. 39 (6), pp. 2984-2998. <i>Date of Electronic Publication: </i>2022 May 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Health+Communications+Inc%22">Health Communications Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8611864 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1865-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220741238X%22">0741238X </searchLink><i>NLM ISO Abbreviation: </i>Adv Ther
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35503499
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s12325-022-02162-w
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2984
    Titles:
      – TitleFull: Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Okada AA
      – PersonEntity:
          Name:
            NameFull: Takahashi K
      – PersonEntity:
          Name:
            NameFull: Ohji M
      – PersonEntity:
          Name:
            NameFull: Moon SC
      – PersonEntity:
          Name:
            NameFull: Machewitz T
      – PersonEntity:
          Name:
            NameFull: Sasaki K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2022 Jun
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1865-8652
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Advances in therapy
              Type: main
ResultId 1